Palatin Supports FDA Advisory Committee’s Recommendation to Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder

Press Releases / By

CRANBURY, N.J., June 4, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) – Today’s FDA Advisory Committee’s recommendation for the approval of flibanserin is an important step forward in women’s health, as the decision addresses the important need for the women living with hypoactive sexual desire disorder, or HSDD, to have an approved treatment option. …

Palatin Supports FDA Advisory Committee’s Recommendation to Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder Read More »